We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Rhinostics Features New RHINObot Automated Decapper at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022

Rhinostics Inc. More...

(Waltham, MA, USA) is participating at this year’s MEDICA in Düsseldorf, Germany where it is showcasing the new RHINObot decapper instrument that enables laboratories to transit to hands-free swab and other sample workflows in order to bring efficiencies, labor cost savings, reproducibility and reliability for robotic workflows that truly link sample in to test results out.

Rhinostics has partnered with LVL technologies GmbH (Crailsheim, Germany) to launch the RHINObot, a customized version of LVL’s successful decapper instrument that enables both the RHINOstic and VERIstic automated collection devices to offer a complete solution for hands-free sample-in to result-out workflows. The combined solution increases sample throughput while reducing labor requirements, decreasing turnaround times, and bringing consistency, efficiencies and cost savings to laboratories testing with swab and small-volume blood collection devices. By combining the Rhinostics’ sample collection device ingenuity with decapper technology, laboratories can benefit from an instantly scalable automated swab and small volume blood collection processing workflow. Automation breaks through manual bottlenecks during capping and recapping steps so that laboratories can increase throughput and consistency while also decreasing cumbersome steps as well as reagent and labor costs.

As part of the partnership, the RHINObot has been optimized for use with the RHINOstic Automated Swab – a patent-pending sample collection device that integrates a unique polypropylene-based swab with an automatable cap. Nasal, buccal, or vaginal samples may be comfortably collected in a clinical setting or easily self-collected as part of an at-home test kit. After collection, the swab is securely screwed into a small, barcoded transport tube. This transport tube may be shipped without use of viral transport or other media to reduce reagent costs as well as risks of leaking, accidental biohazard exposure, and potential PCR interference due to VTM or other media components. Dry shipment also enables greater sample concentrations to boost confidence in sensitive PCR, next generation sequencing (NGS), ELISA methods, even at very low pathogen levels. Once in the laboratory, samples may be loaded onto the RHINObot for automated decapping and capping of up to 96 samples in less than one minute. This hands-free workflow eliminates user variability and reduces labor time by up to 80+% to significantly decrease per-test costs.

“Today, researchers, clinicians, and patients alike expect more when it comes to sample collection and diagnostic workflows from respiratory pathogens, sexually transmitted infections, genetic testing to cancer biomarkers and much more,” explained Cheri Walker, PhD, President and CEO of Rhinostics. “We’re excited to expand our partnership with LVL, our supplier of high-quality collection tubes to Rhinostics during the pandemic and beyond. The companies have enjoyed a close relationship, and we can now offer a full solution for our customers by launching a customized version of LVL’s robust decapper instrument to the market.”

“We are extremely pleased to expand our partnership with Rhinostics,” said Martin von Lueder, Chief Executive Officer of LVL. “We have watched Rhinostics bring industry changing, purpose-built sample collection devices that are automation-enabled to the market. The LVL decapper instrument is the perfect complement to their consumables, allowing improvements to inefficient swab and blood collection workflows. Additionally, we look forward to offering the Rhinostics products to our customers.”

Related Links:
Rhinostics Inc. 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Portable POCT Blood Gas Analyzer
BD100
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.